Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nothing is in the bag just yet though the company is well placed for a further breakthrough in the biotherapeutic space following suit after Seres. As we have remarked before, the risk/return prospects are probably among the most attractive for the sector and possibly across a number of sectors!
All projects are very worthwhile but I'm most excited about the prospect of a biotherapeutic in oncology. After all, as per p.9 of the July presentation: www.4dpharmaplc.com/application/files/9815/9482/4216/4D_pharma_Management_presentation_July_2020_FINAL_web.pdf
"FIRST-IN-CLASS POSITIVE CLINICAL OBSERVATIONS FOR A LIVE BIOTHERAPEUTIC IN ONCOLOGY" ... whereby clinical benefit has been observed in 33% of the case vs. the threshold of 10% for further research to be carried out.
I'd say PHE, proof of concept is now being built. If proven (looks very good), this should build nicely over the next few years.
License deal in the UK (now) and other countries (probable).
It rose considerably a while back, but when the first plant is in commission should really do well.
Not a short term play, more a long-term build.
Yes I know £5 wouldn’t surprise me but I reckon £2 to £250 minimum so anything after that is a bonus
Consider CNR and KEFI, two gold explorers moving to mine production in the next 18-24 months.
Do you feel this could do £2 without news Zengah
Ideas wanted for 10 AIM 10x multibaggers for the next 10 years. Focus on disruptive technologies, preferably with a MOAT. My short list of 10 is: #AVCT #DDDD #EQT #IKA #MXCT #PYC #RENX #SCE #TILS #VDTK More suggestions welcomed!